Life Sciences Business Development in 2026: What Has Actually Changed

Imen Jelassi
Apr 16, 2025
5 min read

Updated: 11 hours ago

Most trend articles list technologies. This one lists the five shifts that actually changed how a small CRO, CDMO or biotech service provider wins clients, with the data behind each one and what to do about it in the next two quarters.

1. Capital is abundant in aggregate and tight at the entry point

Global venture funding reached 425 billion dollars across more than 24,000 companies in 2025, up 30 percent from 328 billion dollars in 2024, according to Crunchbase. Healthcare and biotech was the second largest sector, at roughly 71.7 billion dollars.

The distribution matters more than the total. HSBC Innovation Banking reported biotech venture funding of 7 billion dollars in the first quarter of 2025 and 4.8 billion dollars in the second, with first financings falling from 2.6 billion dollars to 900 million dollars, as reported by BioPharma Dive.

What it changes for BD. Your early-stage biotech prospects have less certainty about their next round, so programs pause more often and for longer. Providers that plan for pauses win. Providers that treat a quiet account as a lost account do not. Consistency of contact through the quiet months is now a competitive advantage rather than good manners.

2. Outsourcing demand keeps compounding

The global pharmaceutical CRO and CDMO market was estimated at 254.65 billion dollars in 2025 and is projected to reach 277.16 billion dollars in 2026, growing at a compound annual rate of 8.84 percent through 2035, according to Towards Healthcare. Our own analysis of the segment is in CDMO market size 2026.

What it changes for BD. Very little, unless you act on it. A growing market does not distribute itself, and sponsors do not go looking for providers they have never heard of. Market growth is a tailwind, and a tailwind only helps a company already moving. The providers that convert this demand are the ones running consistent outbound, not the ones waiting for inbound.

3. Buyers now start their research inside AI assistants

This is the genuinely new one. A growing share of first-stage vendor research happens inside ChatGPT, Perplexity, Gemini and Google AI Overviews rather than on a classic results page. The buyer arrives at your site already holding a shortlist they did not build on your site.

Two consequences follow, and they are not the same problem.

Being rankable is no longer sufficient. A page can rank on page one and still never be quoted in the answer a buyer actually reads.
Being quotable is a distinct discipline. Assistants cite content that answers an explicit question in self-contained sentences, with named sources and concrete figures, rather than content that builds an argument over five paragraphs.

What it changes for BD. Your definitional content matters more than your promotional content. If your site does not answer the question a buyer types in plain language, the assistant answers it with someone else's page. See our guide to generative engine optimization for life sciences.

One caveat, stated plainly. Public benchmarks on how much B2B research now runs through assistants vary widely and most come from vendors selling the solution. The direction is observable. The precise share is not something we would present as verified.

4. Supply chain policy is reshaping partner selection

The BIOSECURE Act has pushed US sponsors to reconsider their manufacturing partners and to favour US and allied CDMOs, and comparable supply chain pressures in the UK and Europe are moving sponsors toward partners they can audit. We covered the mechanics in the BIOSECURE Act and the CDMO reshoring opportunity.

What it changes for BD. Reshoring creates a window, not a pipeline. The sponsors reassessing their partners are doing so quietly, on their own timeline, and they will shortlist providers they already know. The commercial task is to be known before the reassessment, which means outbound now rather than a campaign when the window is visible to everyone.

5. The fractional model became the default for small providers

For a company below the volume that justifies a full-time VP of Sales, the choice used to be an expensive hire or a generalist agency. Neither works well in this sector. A full-time hire takes around twelve months and a senior salary before qualified pipeline appears. A generalist agency measures activity rather than qualified pipeline, and technical buyers ignore generic outreach.

What it changes for BD. Fractional business development gives a small provider a senior BD function part-time, typically one to three days per week, with a faster start and a lower retainer. It is now a standard option rather than a stopgap, and it is the model most small CROs and CDMOs should evaluate first.

What has not changed

Three things are worth stating, because a trend list can imply that everything is new.

Cycles are still long. The pharmaceutical B2B sales cycle averages roughly 138 days and complex CRO or CDMO engagements often exceed twelve months.
Committees are still large. Buying groups commonly run six to thirteen stakeholders across science, operations, quality, procurement and finance.
Scientific credibility is still the price of entry. A prospect can tell within one conversation whether the person across the table understands their modality and their regulatory path.

Any tactic that ignores these three fails regardless of how current it is.

What to do in the next two quarters

Write the definitional content. For each service you sell, publish a plain answer to the question a buyer would type, in self-contained sentences of fifteen to twenty-five words. That is what an assistant can quote.
Instrument the funnel. Track stage-to-stage conversion and the reasons accounts disqualify. Teams that review pipeline velocity weekly report far higher forecast accuracy than teams that check in sporadically.
Build a nurture track for paused programs. Given funding volatility, a documented sequence for accounts that go quiet is worth more than a new campaign.
Pick one market and work it properly. A shallow presence in three territories produces less pipeline than a worked presence in one.
Decide the commercial model deliberately. Full-time hire, fractional, or neither for now. Drifting into a hire because the board expects one is the most expensive of the three.

Frequently asked questions

What is changing in life sciences business development in 2026?

Five shifts: capital is concentrated in later rounds, outsourcing demand keeps growing, buyers start research inside AI assistants, supply chain policy is reshaping partner selection, and fractional BD has become a standard model for small providers.

How much venture funding went into healthcare and biotech in 2025?

Roughly 71.7 billion dollars globally, the second largest sector within total venture funding of 425 billion dollars, according to Crunchbase. Biotech first financings fell to 900 million dollars in the second quarter of 2025.

How big is the pharmaceutical CRO and CDMO market in 2026?

Projected at 277.16 billion dollars in 2026, up from 254.65 billion dollars in 2025, growing at a compound annual rate of 8.84 percent through 2035, according to Towards Healthcare.

Why does generative engine optimization matter for business development?

Buyers increasingly build their shortlist inside ChatGPT, Perplexity and Google AI Overviews before visiting any website. Content has to be quotable in self-contained sentences, not only rankable on a results page.

Is a full-time BD hire still the right model for a small CRO or CDMO?

Only above the volume that keeps a senior person busy. Below that, fractional business development delivers the same function part-time, with a faster start and a lower retainer than a twelve month ramp to first pipeline.

Build the pipeline these shifts reward

Corstrate is a PharmD-led business development consultancy for small and mid-sized life sciences service providers in the US and UK markets. If you want a commercial plan built on these shifts rather than on a trend list, get in touch.